Skip to main content

The role of telomerase in human cancer develpment and an evaluation of its potencial as a therapeutic target

Objective

Telomerase is an attractive target at which to aim novel cancer drugs because it maintains tumor cell immortality, and is inactive in the majority of normal human cells. In this project we will determine the precise molecular mechanisms by which telomerase is repressed in normal cells and activated in human cancer progression. Genetic inhibitors of telomerase will be developed and used to provide unequivocal evidence that anti- telomerase strategies induce replicative senescence in cancer cells, in the absence of cellular resistance machanisms. Novel reagents and procedures will be established for use in telomerase-based cancer diagnosis and in prognostic evaluations. Small molecule lead compounds (from a natural product library) that act as potent inhibitors of telomerase will be identified and characterized, as a basis for anti-telomerase drug development.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

BRUNEL UNIVERSITY
Address
Kingston Lane
Uxbridge
United Kingdom

Participants (7)

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Germany
Address
Fahnenbergplatz
79085 Freiburg (In Breisgau)
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain
Address
Campus De La Universidad Autonoma De Madrid
28049 Madrid
GERMAN CANCER RESEARCH CENTER
Germany
Address
Im Neuenheimer Feld 280
69120 Heidelberg
INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER
Switzerland
Address
155,Ch. Des Boveresses 155
1066 Epalinges
MEDICAL UNIVERSITY CENTER
Germany
Address
Hugstetterstr.55
79106 Freiburg (In Breisgau)
UNIVERSITY OF GLASGOW
United Kingdom
Address
University Avenue
G12 8QQ Glasgow
UNIVERSITY OF UMEAA
Sweden
Address
Universitetsomraadet
901 87 Umeaa